IMAGE GALLERY:
Avicenna Alliance Welcomes the Notified Body TÜV SÜD as a New Partner
08/10/2025
BACK
The Avicenna Alliance is delighted to welcome TÜV SÜD as its newest Partner. TÜV SÜD is a leading Notified Body operating across multiple regulatory territories, including the EU, the United States, the UK, and Asia. With more than 150 years of experience, a presence in 1,000 locations worldwide, and over 30,000 employees, TÜV SÜD is a trusted global partner in testing, inspection, certification, and training solutions.
At the forefront of medical device regulatory affairs, TÜV SÜD actively engages with Artificial Intelligence, Software as a Medical Device (SaMD), Orphan Devices, and breakthrough technologies. The organization recognizes in silico medicine as a critical milestone in regulatory development—an area where collaboration between industry, healthcare, academia, and regulators is essential to ensure computational modelling becomes an integral part of the medical device sector.
“It is an honour for TÜV SÜD to now be part of the global alliance that Avicenna represents and to work with stakeholders from around the world to bring in silico and computational modelling into the medical device regulatory lexicon”, said Surash Surash, Clinical Reviewer at TÜV SÜD.
"The Avicenna Alliance is delighted to welcome TüV SüD as an important partner. Together we will work to increase the presence of in silico evidence (ISE) in the regulatory approval process in Europe", added Thierry Marchal, President and Secretary General of the Avicenna Alliance.
The Avicenna Alliance looks forward to working with TÜV SÜD in advancing the adoption of in silicomethods and shaping future regulatory frameworks that will accelerate innovation and patient access to safe and effective medical technologies.
